Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Thus, this study was designed to compare the changes in bone mineral density (BMD) and bone turnover levels in mice and postmenopausal osteoporotic patients, both with and without T2DM, following treatment with rhPTH(1-34) or alendronate (ALN).

Why It Was Studied

However, there are few studies comparing the anti-osteoporosis effects of anabolic drugs and anti-resorptive drugs in patients with T2DM.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Both DM and control (CON) mice were then randomly assigned to receive either normal saline, rhPTH or ALN treatment.

Postmenopausal patients with osteoporosis (OP) and postmenopausal patients with both osteoporosis and type 2 diabetes (DOP) were recruited and randomly assigned to receive either rhPTH(1-34) or ALN treatment for a period of one year.

How the Study Was Run

The design is described as randomized and open-label.

The participants were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

Nothing was hidden in this open-label Parathyroid Hormone (PTH 1-84) study: the participants and staff both knew the treatment.

The timeline in the abstract includes one year.

In the clinical study, a single-center, prospective, open-label, randomized controlled clinical trial was conducted.

Changes in BMD and bone turnover levels were assessed in all groups.

What Was Measured

Topics PubMed links to this paper include Alendronate, Diabetes Mellitus, Type 2, Mice, Bone Density, Mice, Inbred C57BL, Bone Density Conservation Agents and Diabetes Mellitus, Experimental.

Author keywords: bone mineral density, bone turnover, diabetic bone disease and rhPTH(1-34).

What This Means in Plain Language

The paper is a randomized and open-label study of Parathyroid Hormone (PTH 1-84) over one year.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.